Expert in Neuroscience, Auto-Immune Drug Development, and the CDMO Sector
Expert ID: 739654 United Kingdom
Oxford-educated, he currently holds a leadership role in the commercial development of a novel asset for the treatment of several rare auto-immune indications.
He possesses a deep appreciation of the inevitable trade-offs in drug development -- e.g., speed to market vs. asset differentiation). He established the competitive intelligence function at mid-size European pharma company. He has also served as strategic partner for the company's Alzheimer disease program, where he delivered insights impacting decision making and investment options for the therapy area.
Expert has also been a principal consultant to global pharmaceutical contract manufacturers on corporate strategy, manufacturing demand, and competitor positioning. He was responsible for building a boutique consultancy that counted 8 of the 10 leading CDMOs as clients, increasing sales over five fold. During this time he was a keynote speaker at industry events. He was an advisor on market entry strategy to GSK on contract manufacturing.
|Year: 1994||Degree: D.Phil||Subject: Neuroscience||Institution: University of Oxford|
|Year: 1990||Degree: Msc||Subject: Neuroscience||Institution: Institute of Psychiatry, University of London|
|Years: 2018 to 2022||Employer: UCB||Title: Director R&D Neurology||Department: Corporate Finance|
Responsibilities:Head of commercial insight into early pipeline asset development for Anti-Tau Mab in Alzheimer’s disease. Spearheaded competitor intelligence, market landscape and therapy area overview for joint venture with Genentech. Played key role in end-to-end analysis for accelerated clinical programme for Bepranemab.
Strategic partner for Alzheimer disease. Delivered insights impacting decision making and investment options for the therapy area.
Led review of the company's neuroscience strategy, challenging dependency on epilepsy portfolio. Questioned legacy decision-making, identifying protracted governance decisions and poor development timelines.
Partnered Licensing group to explore business development opportunities in epilepsy. Was accountable for long-term forecasting of epilepsy market and prospects for rare epilepsy acquisitions.
Initiated new benchmark program of R&D productivity to estimate ROI against direct competitors. Analyzed development performance in Myasthenia Gravis (endpoints and protocol amendments).
|Years: 2012 to 2018||Employer: Globaldata||Title: Director of Market Intelligence||Department:|
Responsibilities:Principal consultant to global pharmaceutical contract manufacturers on corporate strategy, manufacturing demand, and competitor positioning. Advisor on market entry strategy to GSK on contract manufacturing. Consultant to top 5 US contract manufacturers on M&A targets.
Author of definitive industry reports, leveraging new and unparalleled data resources for consultancy, propelling Strategic Advantage Database into the premier intelligence platform, with subscribers including pharmaceutical companies, contractors, and McKinsey, BCG, Bain, and PWC.
|Years: 1999 to 2007||Employer: Cardinal Health||Title: Strategic Intelligence||Department: Corporate|
Responsibilities:Directed global biopharmaceutical market and competitor analysis in a $2 billion division. Responsibilities included corporate and strategic planning, M&A, and in-licensing.
Advised C-suite on competitor entry, new drug performance, FDA product clearance, and patent expiry.